Background The proportion of critically ill COVID-19 patients has collapsed hospital care
worldwide. The need for alternative therapies for this group of patients is imperative. This …

Acting on the cytokine cascade is key to preventing disease progression and death in
hospitalised patients with COVID-19. Among anti-cytokine therapies, interleukin (IL)-6 …

Summary Hyperimmune immunoglobulin (hCoV-2IG) generated from SARS-CoV-2
convalescent plasma (CP) are under evaluation in clinical trials. Here we explored the …

Introduction: Severe acute respiratory syndrome causing coronavirus SARS-CoV-2
(coronavirus disease 2019 (COVID-19)) has recently resulted in the recent global pandemic …

Monoclonal antibodies (MAbs), convalescent plasma (CP) and hyperimmune intravenous
immunoglobulins are routinely used to treat COVID-19 patients with autoimmune disorders …

Background Hyperimmune immunoglobulin (hIVIG) contains polyclonal antibodies, which
can be prepared from large amounts of pooled convalescent plasma or prepared from …

We described three critically ill patients with coronavirus disease 2019 (COVID-19) in
Wuhan, China, featured with profound inflammation and treated with blood purification …

The ongoing pandemic coronavirus disease 2019 (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) is rapidly spreading and has resulted in …

Background There are several types of coronaviruses that infect humans and cause
disease. The latest is severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) …

Antibody therapies such as convalescent plasma and monoclonal antibodies have emerged
as major potential therapeutics for coronavirus disease 2019 (COVID-19). Immunoglobulins …